STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 215.3

Change

-7.45 (-3.34)%

Market Cap

USD 0.71B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-1.01 (-2.22%)

USD 55.36B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-11.50 (-2.20%)

USD 14.29B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-8.35 (-2.24%)

USD 13.82B
WRD:PA HSBC MSCI World UCITS ETF

-0.71 (-2.08%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-4.50 (-1.76%)

USD 9.11B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-7.05 (-1.60%)

USD 8.85B
WLD:PA Lyxor UCITS MSCI World D-EUR

-7.06 (-2.10%)

USD 7.99B
HHH:PA HSBC S&P 500 UCITS ETF

-1.16 (-2.21%)

USD 7.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

N/A

USD 6.91B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.10 (+1.34%)

USD 5.25B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.77% 71% C- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.77% 71% C- 61% D-
Trailing 12 Months  
Capital Gain -1.87% 16% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.87% 15% F 37% F
Trailing 5 Years  
Capital Gain 66.25% 43% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.25% 39% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 9.57% 56% F 62% D
Dividend Return 9.57% 55% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.85% 76% C+ 88% B+
Risk Adjusted Return 121.96% 93% A 96% N/A
Market Capitalization 0.71B 72% C 75% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike